These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18756039)

  • 1. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia.
    Ishikawa T; Mizuno K; Nakaya N; Ohashi Y; Tajima N; Kushiro T; Teramoto T; Uchiyama S; Nakamura H;
    Circ J; 2008 Oct; 72(10):1576-82. PubMed ID: 18756039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial.
    Uchiyama S; Nakaya N; Mizuno K; Ohashi Y; Tajima N; Kushiro T; Teramoto T; Nakamura H;
    J Neurol Sci; 2009 Sep; 284(1-2):72-6. PubMed ID: 19423132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pravastatin on exercise electrocardiography test performance and cardiovascular mortality and morbidity in patients with hypercholesterolemia: Lipid Intervention Study in Kyoto.
    Sasaki S; Nakagawa M; Nakata T; Azuma A; Sawada S; Takeda K; Asayama J;
    Circ J; 2002 Jan; 66(1):47-52. PubMed ID: 11999665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators.
    Marschner IC; Colquhoun D; Simes RJ; Glasziou P; Harris P; Singh BB; Friedlander D; White H; Thompson P; Tonkin A;
    J Am Coll Cardiol; 2001 Jul; 38(1):56-63. PubMed ID: 11451296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT).
    Margolis KL; Dunn K; Simpson LM; Ford CE; Williamson JD; Gordon DJ; Einhorn PT; Probstfield JL;
    Am Heart J; 2009 Dec; 158(6):948-55. PubMed ID: 19958861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of high-density lipoprotein cholesterol control during pravastatin treatment in hypercholesterolemic Japanese with type 2 diabetes mellitus: a post hoc analysis of MEGA study.
    Nishimura R; Sone H; Nakagami T; Tajima N
    Diabetes Res Clin Pract; 2013 May; 100(2):e31-3. PubMed ID: 23522341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
    Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
    Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin.
    Nakamura H;
    Atheroscler Suppl; 2007 Aug; 8(2):13-7. PubMed ID: 17586102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ; Davidson MH; Caplan RJ; Pears JS
    Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly.
    Akao H; Polisecki E; Kajinami K; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J; Packard C; Buckley BM; Schaefer EJ
    Atherosclerosis; 2012 Feb; 220(2):456-62. PubMed ID: 22192511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of the month. The ALLHAT-LLT trial].
    Kulbertus H; Scheen AJ
    Rev Med Liege; 2003 Jan; 58(1):53-8. PubMed ID: 12647600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data.
    Teramoto T; Ohashi Y; Nakaya N; Yokoyama S; Mizuno K; Nakamura H;
    Circ J; 2008 Oct; 72(10):1569-75. PubMed ID: 18762707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pravastatin: a review of its use in elderly patients.
    Bang LM; Goa KL
    Drugs Aging; 2003; 20(14):1061-82. PubMed ID: 14651445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of serum total cholesterol and other risk factors to risk of coronary events in middle-aged and elderly Japanese men with hypercholesterolemia: the Kyushu Lipid Intervention Study.
    Iwashita M; Matsushita Y; Sasaki J; Arakawa K; Kono S;
    Circ J; 2004 May; 68(5):405-9. PubMed ID: 15118279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese.
    Teramoto T; Nakaya N; Yokoyama S; Ohashi Y; Mizuno K; Nakamura H;
    J Atheroscler Thromb; 2010 Aug; 17(8):879-87. PubMed ID: 20543522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.